Exchange: NYSE·Updated 07:59 PM EDT
News
all
press releases
Abbott Laboratories vs. Johnson & Johnson: Which Healthcare Stock Is a Better Buy in 2026?
Key PointsAbbott Laboratories leverages a diversified portfolio across medical devices and diagnostics, bolstered by its recent acquisition of Exact Sciences...
Nasdaq News: Markets
More News
Should You Invest in Liquidia Corporation Stock Ahead of Q2 Earnings?
LQDA heads into its Q2 earnings with Yutrepia driving growth, rising profitability and a self-funded pipeline as investors watch quarterly performance.
Zacks
Johnson & Johnson Shares Edge Higher as $3.5B Biotech Moves Expand Oncology Pipeline
Johnson & Johnson (NYSE: JNJ) shares are edging higher on Friday as investors digest two major biotech pipeline moves.read more...
Benzinga
ABBV Beats on Q2 Earnings & Sales, Cuts '26 EPS View, Stock Down
AbbVie tops Q2 earnings and revenue estimates on strong immunology drug sales, but a lower 2026 EPS outlook tied to the Apogee deal weighs on shares.
Zacks
Should You Buy, Sell or Hold Merck Stock Ahead of Q2 Earnings?
MRK heads into Q2 earnings with acquisition costs, Keytruda strength and Gardasil challenges likely to shape results. Is the stock still worth holding?
Zacks
Johnson & Johnson Advances Cancer and Immunology Treatments With Major Biotech Deals
Johnson & Johnson expands its biotech pipeline with Firefly Bio acquisition and a strategic partnership with Sail Biomedicines.read more...
Benzinga
Johnson & Johnson (JNJ) is a Top-Ranked Momentum Stock: Should You Buy?
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Zacks
Johnson & Johnson's RYBREVANT FASPRO (amivantamab and hyaluronidase-lpuj) receives U.S. FDA Priority Review as potential first-in-class EGFR- and MET-targeted subcutaneous treatment for advanced head and neck cancer
Johnson & Johnson's RYBREVANT FASPRO (amivantamab and hyaluronidase-lpuj) receives U.S. FDA Priority Review as potential first-in-class EGFR- and MET-targeted subcutaneous treatment for advanced head and neck cancer Johnson & Johnson's RYBREVANT FASPRO (amivantamab and hyaluronidase-lpuj) receives...
PR Newswire
Futures Rise As Oil Drops, Bond Selling Slows, Meta Tumbles And Microsoft Soars
Futures Rise As Oil Drops, Bond Selling Slows, Meta Tumbles And Microsoft Soars Futures rebound (for now) following yesterday's Fed-induced meltdown as the market is clearly questioning Warsh's credibility and potential usage of non-standard tools to fight inflation, pushing the yield...
Zero Hedge
Johnson & Johnson Completes Acquisition of Firefly Bio, Inc. to Advance Next-Generation Oncology Innovation
Johnson & Johnson (NYSE: JNJ) today announced the successful completion of its acquisition of Firefly Bio, Inc., a biotechnology company advancing its proprietary Firelink degrader antibody conjugate (DAC) platform, for $1 billion in cash. The Firelink DAC platform expands Johnson & Johnsons...
Business Wire
<
1
2
>

Advertisement|Remove ads.